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Umbilical cords as a source of stem cells are of increasing interest for cell therapies as they present little ethical consideration and are
reported to contain immune privileged cells which may be suitable for allogeneic based therapies. Mesenchymal stem cells (MSCs)
sourced from several different cord regions, including artery, vein, cord lining, and Wharton’s jelly, are described in the literature.
However, no one study has yet isolated and characterised MSCs from all regions of the same cord to determine the most suitable
cells for cell based therapeutics.
1. Introduction
Thehuman umbilical cord (UC) contains distinct anatomical
regions comprising two umbilical arteries, umbilical vein,
cord lining, and Wharton’s jelly (the tissue which surrounds
and supports the blood vessels). Each of these regions has
been described previously in the literature as giving rise to
a great number of fibroblastoid MSCs [1]. Cells isolated from
arteries, vein, cord lining and Wharton’s jelly have all been
shown to be plastic adherent and to be multipotent, differen-
tiating into many cell types such as osteoblasts, adipocytes,
chondrocytes, hepatocytes, and neural and cardiac cells [2–
4].They also express markers typical of bonemarrow derived
MSC (bMSC) [5–7], whilst being negative for haematopoietic
and macrophage markers.
For many years, bone marrow has been considered the
“gold standard” for the derivation of MSCs for human stem
cell engineering. However, extraction comes with ethical
constraint and problems associated with painful harvesting
and donor site morbidity. UCs appear to show potential as a
source of MSCs for a number of reasons; they are considered
medical waste, and therefore their use in research has little
ethical concern; they proliferate rapidly in culture and are
thought to be immune privileged [2, 6]. In addition, bMSC
have shown notable changes with increasing patient age, such
as reduction in available cell number, longer doubling times,
and lower differentiation potential in vitro [8, 9]. Like bMSC,
UC MSCs are thought to have an immune privileged status
and an immunomodulatory phenotype capable of suppress-
ing the immune response in vitro [6], which makes them an
attractive candidate for allogeneic cell based therapies.
UC MSCs offer a favourable source of primitive MSCs
that can be cryogenically stored in cell banks, thawed and
expanded for therapeutic uses. Although many studies char-
acterising cell populations arising from specific cord regions
have been reported [7, 10–14], there are no known single
studies which have aimed to isolate, culture, and characterise
cells from all cord regions from the same cord.
Many review articles draw together comparisons of
characterised cell populations isolated from different cord
regions (15, 16, and 17) and report many differences as well
as similarities between these cell populations. The authors of
these articles often draw attention to the fact that many of
the differences could be attributable to variation in isolation
or culture technique as well as different handling between
research groups. A recent review article states that MSCs
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Figure 1: (a) Partially dissected human UC showing umbilical arteries, vein, Wharton’s jelly, and cord lining. (b) Umbilical cord cells from
mixed cord (and for individual regions) were heterogeneous in morphology when viewed in phase contrast microscopy soon after isolation.
This became more uniform with time in culture. (1) P0 ∼6 days. (2) P0 ∼20 days. (3) P2. Scale bars represent 100 𝜇M.
isolated from the various compartments of the umbilical
cord have yet to be compared with each other [15]. The
main focus of the study was therefore to investigate the
cell populations arising from four of the distinct anatomical
regions of the same human umbilical cord and compare
them to a preparation of cells isolated from the whole
cord. Therefore providing information on the isolation and
culture of a population of cells is worthy of further study
and characterisation. We describe for the first time basic
characterisation of MSCs obtained from each of the four
distinct regions carefully dissected from the same umbilical
cord, providing a direct and relevant comparison of cells with
the potential for tissue engineering and repair. In addition, we
have examined the cell population from an enzymatic digest
of a section of complete umbilical cord and compared all
populations to bone marrow derived MSCs.
2. Materials and Methods
2.1. UC Cellular Isolation and Subculture. All samples were
obtained after patients’ provided informed consent
(favourable ethical approval was given by the National
Research Ethics Service; 10/H10130/62). UCs were collected
from the Robert Jones andAgnesHuntOrthopaedicHospital
(RJAH) maternity unit and processed within 24 h of natural
delivery. Whole cord was washed in sterile phosphate
buffered saline (PBS) (Life Sciences, UK) ∼three times to
remove red blood cells, immersed in 70% ethanol (Sigma,
UK) for 30 s, and then immediately washed in PBS before
further processing. Approximately 2-3 cm of whole cord was
taken for processing as mixed cord, and approximately 6 cm
of whole cord was dissected to obtain artery, vein, Wharton’s
jelly and cord lining (Figure 1(a)). Explant cultures were
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obtained from each region which was weighed, minced into
small pieces (∼2mm3) with a sterile scalpel, placed into 6
well plates (Sarstedt, UK), and grown in media containing:
Dulbecco’s Modified Eagle’s Medium (DMEM F12), foetal
calf serum (FCS) (10%) (Life Sciences, UK), and penicillin
and streptomycin (P/S) (Life Sciences, UK). Tissue explants
were removed after 21 days in culture. Adherent cells were
passaged upon reaching 70% confluence and reseeded at 5 ×
103/cm2 in either 25 cm2 or 75 cm2 tissue culture flasks
(Corning Falcon, UK) for growth kinetics or for further
culture expansion (resp.). Viable cells were counted by trypan
blue (Sigma) exclusion in a haemocytometer. In addition,
for mixed cord cultures the whole cord was cut into small
pieces (∼2mm3) and digested with collagenase (1mg/mL of
type I) (Sigma, UK) for 1 h at 37∘C. Tissue was removed from
the digest and the supernatant centrifuged at 80 g for 10min;
the pellet was then resuspended in 5mL of the previous
medium and plated in a 25 cm2 tissue culture flask. Medium
was changed every 2-3 days and cells were maintained in a
humidified atmosphere at 5% CO
2
at 37∘C.
In addition human bMSCs were obtained for comparison
from bone marrow aspirates or bone chips harvested from
the iliac crest of individuals undergoing spinal fusion in
the treatment for back pain. Samples used in differentiation
studies were from patients aged 29, 40, and 80 years and those
used for growth kinetics were from patients aged 34, 42, and
44 years.
Bone chips were perfused with DMEM F12, supple-
mented with FCS (10%) and (P/S) (1%). Mononuclear cells
were isolated by density gradient centrifugation at 900 g for
20 minutes over Lymphoprep (Fresenius Kabi Norge, AS).
The buffy coat layer was resuspended in complete media and
centrifuged at 750 g for 10min to pellet white blood cells.The
resulting pellet was plated out in DMEM F12, FCS (20%),
and P/S (1%) medium (Invitrogen) at a seeding density of
20 × 106 cells per flask. Bone marrow aspirate samples were
diluted 1 : 1 with sterile saline and layered over Lymphoprep,
centrifuged at 900 g for 20 minutes, and plated as described
forUCMSCs.After 24 h, nonadherent cells were removed and
adherent cells were cultured in monolayer and maintained
in a humidified atmosphere of 5% CO
2
at 37∘C through to
passage (P) 2-3 in DMEM F12, FCS (10%), and P/S medium.
2.2. Growth Kinetics Analysis. To calculate doubling time
(DT), cells were harvested, counted, and replated when they
reached 70% confluency. Doubling time was calculated using
the formula DT = (𝑡2 − 𝑡1) ln(2)/ ln(𝑛2 − 𝑛1) where 𝑛2 is
the cell number at harvesting, 𝑛1 is the cell number at plating
and, 𝑡2 and 𝑡1 are the number of days in culture [16]. A total of
four cords were used for growth kinetics analysis and a total
of three patients for bMSC.
2.3. Statistics. All data from four cords was normally dis-
tributed and differences were calculated using a one-way
ANOVA with Bonferroni post hoc test. Levels of significance
are indicated ∗𝑃 < 0.05, ∗∗𝑃 < 0.01.
2.4. Immunoprofiling. Flow cytometry was used to assess
the MSC immunoprofile of UC cells, using the standard for
MSC described by the position paper of the International
Society for Cellular Therapy (ISCT) [17]. Cells (P2-3) were
harvested, filtered through a cell strainer (70 𝜇M), pelleted,
resuspended in 2% bovine serum albumin (BSA in PBS),
and counted. One million cells of each population were
used for flow cytometry. Cells were stained with directly
(phycoerythrin) conjugated antibodies against CD14, CD19,
CD31, CD34, CD45, CD90, HLA-DR, CD105 (ImmunoTools,
Germany), and CD73 (Becton Dickinson and Company,
UK). An appropriate isotype-matched control antibody was
used in all analyses. Cells were analysed on FACS scan flow
cytometer using Cell Quest Software (Becton Dickinson,
UK). Cells from all four cord regions plus the whole cord
digest were analysed using flow cytometry for a total of 7
cords. bMSCs from 3 patients were also analysed.
2.5. Assessing Differentiation Potential (or Multipotency). UC
cells at P2-3 were assessed for osteogenic, adipogenic, and
chondrogenic differentiation potentials. Cells were seeded
at a density of 5 × 103/cm2 in 6 well plates and grown in
monolayer in DMEM F12 and FCS (10%) until reaching
∼90% confluency, and at this point the cells were given
the appropriate differentiation medium, either osteogenic
or adipogenic medium for 21 days. Medium was changed
every 2-3 days. Osteogenic differentiation medium con-
tained DMEM F12, FCS (10%), 𝛽-glycerophosphate (10mM),
dexamethasone (10 nM), and L-ascorbic-acid (50𝜇M) [18].
Controls were grown in DMEM F12, FCS (10%). Adi-
pogenic differentiation medium contained DMEM F12, FCS
(10%), insulin-transferrin-selenium-X (ITS) (1%) (Gibco
UK), isobutylmethylxanthine (0.5 𝜇M) (Sigma, UK), dexam-
ethasone (1𝜇M), and indomethacin (100𝜇M). Osteogenic
and adipogenic controls used media containing DMEM F12,
FCS (10%), and P/S. To evaluate the differentiation, in brief,
cells were fixed with buffered formalin (10%) in PBS for
10mins at room temperature and stainedwith oil red-O for 1 h
to assess lipid formation for adipogenesis or naphthol-AS-BI
phosphate and fast red for 1 h to assess alkaline phosphatase
activity for osteogenesis. A total of 6 cords and 3 bMSC
samples (fromdifferent patients) were used for differentiation
studies. Cells were grown in sixwell plates (Sarstedt,UK)with
three replicate wells from each individual cell population for
osteogenic or adipogenic media and three replicate wells as
controls per cell population/sample.
A pellet culture system was used to assess chondrogenic
differentiation potential. Cells (5 × 105) were centrifuged in a
1.5mL eppendorf (500 g for 5min) in 1mL of chondrogenic
medium consisting of DMEM + GlutaMaxTM−1, FCS (2%),
gentamicin (10 𝜇g/mL−1), ITS (1%), ascorbic-acid (0.1mM),
dexamethasone (10 nM), and transforming growth factor 𝛽1
(TGF-𝛽1) (10 ng/mL−1) (Peprotech, UK). Cells were cultured
for 21 days and media changed every 2-3 days. After 21 days,
cell pellets were snap frozen in liquid nitrogen and stored
at −80∘C prior to use. Pellets were sectioned (7 𝜇M) on a
cryostat (Bright Instrument Co., Ltd., Huntingdon, UK) onto
poly-l-lysine coated slides and stained for glycosaminogly-
cans (GAGs) with toluidine blue metachromatic stain.
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The degree of differentiation was estimated and assessed
semiquantitatively by attributing scores ranging from 0 (no
staining) to +++++ (very strong staining) of the final prepa-
rations.
The scoring system was then given a numerical value
ranging from 0 to 5 for statistical analysis using Kruskall-
Wallace with Bonferroni post hoc test.
3. Results
3.1. Dissection of Cord Regions
3.1.1. Expansion of UC MSCs In Vitro. Cells from all regions
of the umbilical cord and the complete cord digest contained
a high number of adherent MSC-like cells which proliferated
rapidly in number. Cells isolated from all the cord regions
proliferatedmarkedly faster than bMSCswithmean doubling
times of 2-3 days at P0 through P3 (Figure 2). bMSCs, in
comparison, had a mean doubling time of ∼5 days (P1-
2) and ∼11-12 days (P2-3). UC cells showed a high degree
of morphological heterogeneity like bMSCs but most cells
had a smaller fibroblastic surface area during early passage
(P0) (Figure 1(a)) which developed into a flattened, increased
surface area coverage by P2-3.
3.2. Flow Cytometry. Flow cytometry immunoprofiling dem-
onstrated that all preparations lacked expression of the
haematopoetic, macrophage, and endothelial markers: CD14,
CD19, CD31, CD34, CD45, and HLA-DR, but remained
immunopositive for markers characteristic of MSCs (CD73,
CD90, and CD105) (Figure 3).
3.3. Differentiation Potential. The definitive demonstration
of multipotency for a cell is the ability to differentiate
towards more than one cell type. Cells isolated from all
cord regions showed the potential to differentiate to varying
degrees as shown by positive osteogenic, adipogenic, and
chondrogenic staining (Figure 4). Adipogenesis was seen
with positive oil red-O staining and osteogenic differenti-
ation was demonstrated with alkaline phosphatase staining
(Figures 4(b) and 4(c)). In addition, toluidine blue stained
chondrogenic pellets indicated the presence of GAGs within
the pelletmatrix although this was seen at different intensities
for each cell preparation.
However, the degree of differentiation of UC cells into
the three lineages tested (osteogenesis, adipogenesis, and
chondrogenesis) varied between patients and between cord
regions. Mixed cord, Wharton’s jelly, and artery showed the
most consistent differentiation for all of the mesenchymal
lineages tested, whilst cells isolated from vein were the most
variable (Figure 4(d)). Cord lining showed poor differentia-
tion potential particularly for osteogenesis compared to cells
from other cord regions.
Mixed cord, Wharton’s jelly, and artery differentiated
consistently down adipogenic and osteogenic lineages. Cells
from vein and cord lining showed consistently poor osteoge-
nesis but better adipogenesis in comparison. Lipid droplets
which formed in cultures from all cord regions were notably
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Figure 2: Doubling time (days) of mesenchymal stem cells (MSCs)
isolated from different regions of umbilical cord and cells isolated
from iliac crest bone marrow at passages 0 to 3. Data shown are
means ± SEM for four cords, bMSCs were taken from three patients.
Levels of significance are indicated ∗𝑃 < 0.05, ∗∗𝑃 < 0.01.
smaller and more cell associated than lipids produced from
bMSCs which were both intracellular and extracellular, with
lipids observed floating in the media prior to staining.
Untreated control cultures, which were grown in regular
medium without adipogenic, or osteogenic differentiation
stimuli, sometimes exhibited varying degrees of spontaneous
fat formation and alkaline phosphatase activity after 21 days of
cultivation (Figure 4(d)). Cultures of vein or Wharton’s jelly
cells showed the greatest propensity for spontaneous differen-
tiation.However, spontaneous differentiation seen in controls
tended to be weaker than differentiation staining seen for the
cells grown in the differentiation media. The scoring system
used in Figure 4(d) was subject to nonparametric statistical
analysis since both osteogenic and adipogenic scorings were
not normally distributed; Kruskall-Wallace with Bonferroni
post hoc test was used to analyse the data. No significant
differences were seen between BMSC, MC, and WJ for
osteogenesis, but there were significant differences between
the following: V and BMSC 𝑃 = 0.007, WJ and CL 𝑃 = 0.01,
and CL and BMSC 𝑃 = 0.0004. For adipogenesis significant
differences were seen between V and BMSC 𝑃 = 0.01 and CL
and BMSC 𝑃 = 0.05.
Cells isolated from all cord regions showed some chon-
drogenic potential, but there were considerable variations in
the intensity of toluidine blue (metachromatic) staining for
GAGs between patients and cord regions. Pellet cultures did
not demonstrate any one cord region as being consistently
better than others for chondrogenic differentiation.
4. Discussion
The available data suggests that the UC MSCs present a
cell family whose components show various degrees of het-
erogeneity and multipotency. This study, with standardised
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Figure 3: Representative flow cytometry profile of five comparative cell populations isolated from one umbilical cord and bone marrow as
required for the International Society for CellularTherapy (ISCT) definition of MSC. A total of seven cords were analysed in this study along
with bMSC from three patients. The purple peak represents the isotype control.
procedures for isolation and culture of UC cells, aimed to
determine the most efficient means to extract and grow
MSCs and to identify the cell population possessing the
greatest potential for further study and later developing as an
allogeneic source of cells or regenerative medicine.
The isolation and culture of MSCs from individual cord
regions including cord vein and the perivascular region [7,
10, 13, 14], Wharton’s jelly [11], and cord lining [12] has been
reported by many groups. However, none of these studies
or indeed any other studies have compared all cord regions
from within the same individual [1]. We describe for the first
time characterisation ofMSCs obtained from each of the four
distinct regions carefully dissected from the same umbilical
cord, providing a direct and relevant comparison of cells with
the potential for tissue engineering and repair. In addition, we
have examined the cell population from an enzymatic digest
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Figure 4: Representative images of (a) chondrogenically-induced cell pellets isolated from different cord regions: cord lining (CL), artery
(A),Wharton’s jelly (WJ), vein (V), mixed cord (MC), and bMSC. Scale bar represents 1000𝜇m. (b) Osteogenic and adipogenic differentiated
cells from MC. (c) Osteogenic and adipogenic differentiated cells from bMSCs. Scale bars represent 100𝜇m and 25𝜇m for osteogenic
and adipogenic images respectively. (d) Scoring of osteogenic and adipogenic differentiation of cells isolated from different regions of the
umbilical cord and cells isolated from ileac crest. +++++ denotes scoring system given to the best differentiation seen from bMSCs. Sdenotes
spontaneous differentiation. NT not tested.
of a section of complete umbilical cord and compared all
populations to bone marrow derived MSCs.
Commonly used criteria for defining MSCs are those
described by ISCT [17]. In the present study, cells isolated
from all cord regions, as well as the whole cord, comply
with them, being adherent to plastic and negative for the
expression of haematopoietic, macrophage, and endothelial
markers (CD14, 19, 31, 34, and 45) but positive for MSC
markers, CD73, 90, and 105. Cells were also HLA-DR
(MHC class II) negative. In addition, cells isolated from all
cord regions differentiated along osteogenic, adipogenic, and
chondrogenic lineages but to varying degrees. Results showed
that cells isolated from Wharton’s jelly and mixed cord had
the best osteogenic and adipogenic differentiation potentials
overall, but cells isolated from all cord regions showed
similar chondrogenic differentiation potential as shown by
toluidine blue metachromatic staining of sulphated GAGs
(Figure 4(a)).
Differentiation to osteoblasts and adipocytes was
similar to bMSCs isolated from three different patients
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(Figures 4(b) and 4(c)). Adipogenic differentiation showed
that UC-derived MSCs produced small lipid vacuoles in
contrast to those of BM-derived MSCs, indicating more
mature adipocytes in BM-derived MSCs than in cultures of
UCMSC. Other studies report smaller lipid droplets from
UCMSC derived from UC blood [19]. BMSCs presented
more committed adipocytes (unilocular lipid vacuoles) than
induced UCMSCs, perhaps, due to UC MSCs maintaining
their multipotency for longer periods in vitro than bMSC
[20].
Review of the current literature suggests that cells isolated
fromWharton’s jelly have the best multipotent differentiation
potential [1], differentiating into bone, fat, and cartilage,
cardiomyocytes [13], neurones [21], muscle cells [22], and
hepatocytes [3]. However, perhaps the reason for Wharton’s
jelly’s apparently greatest differentiation potential in compar-
ison to other regions is due to the fact that cells isolated from
Wharton’s jelly have received themost extensive investigation
[1]. We are not aware of a direct and relevant comparison
between Wharton’s jelly and all other cord derived cells
having previously been carried out in the same study until
now.
Although UC cells are referred to as MSCs throughout
this study, it is possible that some or indeed all of the isolated
cells are in fact pericytes. Experiments have shown that
pericytes are located around endothelial cells in the capillaries
andmicrovessels [23], such that they possess antigenic mark-
ers typical ofMSCs and behave in culture likeMSCs [24].This
would be especially relevant to the cell populations isolated
from cord artery and cord vein. However, this may also be
true of cells isolated from cord lining and Wharton’s jelly as
it has been demonstrated that MSC-like cells originate from
pericytes [19] or that pericytes are indeed MSCs. Like typical
MSCs, pericytes grow proficiently in culture, exhibiting the
morphology and surface antigens of MSCs (CD73, CD90,
and CD105). In addition, pericytes resembled MSCs in terms
of developmental potential because the latter differentiate
clonally into bone, cartilage, and fat cells when cultured under
relevant inductive conditions, which is true of cells isolated
from all cord regions in this study.
This study presents comparative data from four different
individual regions of the human UC, as well as the whole
UC, in comparison to the more conventional source of MSC
from bone marrow. We conclude that MSCs can be found
in all cord regions, and that they are morphologically and
immunophenotypically similar with the panel of markers
used as recommended by the ISCT. The results in this study
suggest that the time-consuming and labour-intensive dissec-
tion of the cord into discrete regions is not necessary to obtain
a valuable population of cells for further study, since mincing
sections of whole cord and subsequent enzymatic digestion
provides cells with MSC-like properties which are as good as
the best individual cord region seen in this study. Extensive
culture expansion of these cells could therefore provide a
bank of cells whichmay be suitable for allogeneic cell therapy.
This would negate the need for sourcing autologous cells, for
example, from adipose tissue or bone marrow, which have
associated problems of donor site morbidity and limited cell
number.
5. Conclusion
In this studyMSCs from four distinct regions of the same cord
(artery, vein, Wharton’s jelly, and cord lining), in addition
to a mixed population of cells from the whole cord, have
been isolated and compared for potentialmusculoskeletal cell
therapy.MSCswere cultured from all individual cord regions,
as well as enzymatically digested whole cord, demonstrated
by their plastic adherence, flow cytometry profile, and ability
to differentiate along osteogenic, adipogenic, and chondro-
genic lineages. Growth kinetics and MSC immunoprofile
showedno significant difference between cells from any of the
populations (or isolates). Osteogenic and adipogenic differ-
entiation studies showed variation between cord regions,with
the best differentiation seen with Wharton’s jelly and whole
cord. Chondrogenic differentiation showed little difference
between cells isolated from different cord regions.
Enzymatic digestion of the whole cord is easy to under-
take, quickly providing a large number of MSC-like cells
compared to cells from explant culture of individual cord
regions. Cells from whole cord differentiated as well as or
better than those isolated from individual cord regions and
therefore have potential as a useful source for obtaining
promising cell populations for further study.
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